Related Experiment Video

Updated: Dec 21, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

32.3K

Peroxisome Proliferator-Activated Receptors as a Therapeutic Target in Asthma

Oxana Yu Kytikova1, Juliy M Perelman2, Tatyana P Novgorodtseva1

  • 1Vladivostok Branch of Far Eastern Scientific Centre of Physiology and Pathology of Respiration, Institute of Medical Climatology and Rehabilitative Treatment, Vladivostok, Russia.

PPAR Research
|May 13, 2020
PubMed

Insights

Peroxisome proliferator-activated receptors (PPARs) are key regulators of inflammation in asthma. Targeting PPARs with natural or synthetic ligands shows promise for novel asthma therapies.

Area of Science:

  • Biochemistry
  • Immunology
  • Pharmacology

Background:

  • Asthma pathogenesis involves complex chronic inflammation, leading to heterogeneity and treatment challenges.
  • Nuclear transcription factors, including peroxisome proliferator-activated receptors (PPARs), regulate inflammatory processes.
  • PPARs influence lipid homeostasis and inflammatory responses, making them a therapeutic target in asthma.

Purpose of the Study:

  • To review the structure, function, and role of PPARs in asthma pathogenesis.
  • To discuss the potential of PPAR ligands as therapeutic agents for asthma.

Main Methods:

  • Literature review of current research on PPARs and asthma.
  • Analysis of signaling mechanisms of PPARs in inflammation.
  • Examination of natural and synthetic PPAR ligands.

Main Results:

  • PPARs are crucial in initiating and resolving inflammation in asthma.
  • Both natural (PUFAs, endocannabinoids, eicosanoids) and synthetic (fibrates, thiazolidinediones) PPAR ligands exhibit anti-inflammatory effects.
  • Understanding PPAR signaling pathways is vital for asthma treatment.

Conclusions:

  • PPARs are significant targets for managing chronic inflammation in asthma.
  • PPAR ligands offer a promising therapeutic avenue for asthma treatment.
  • Further research into PPAR signaling mechanisms can optimize asthma therapy.

More Related Videos

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure08:17

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure

Published on: August 25, 2017

11.4K
Monitoring Stub1-Mediated Pexophagy08:26

Monitoring Stub1-Mediated Pexophagy

Published on: May 12, 2023

1.9K

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.6K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.1K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
1.6K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.9K
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.5K
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K